Dagenais, Gilles R.

Rivaroxaban with or without aspirin in stable cardiovascular disease

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 2,438

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P., Brauer, M., Kutty, V. R., Gupta, R., Wielgosz, A., et al. (2020) · The Lancet

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 2,017

Hyperinsulinemia as an independent risk factor for ischemic heart disease

Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Function and Risk Factors

Cited by 1,699

Association of cardiometabolic multimorbidity with mortality

Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA

Chronic Disease Management StrategiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,155

Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Que´bec Cardiovascular Study

Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,077

Cardiovascular risk and events in 17 low-, middle-, and high-income countries

Yusuf, S., Rangarajan, S., Teo, K., Islam, S., Li, W., Liu, L., Bo, J., Lou, Q., Lu, F., Liu, T., et al. (2014) · New England Journal of Medicine

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 983

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey

Yusuf, S., Islam, S., Chow, C. K., Rangarajan, S., Dagenais, G., Diaz, R., Gupta, R., Kelishadi, R., Iqbal, R., Avezum, A., et al. (2011) · The Lancet

Cardiovascular Health and Risk FactorsLipoproteins and Cardiovascular Health

Cited by 964

Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events

O'Donnell, M., Mente, A., Rangarajan, S., McQueen, M. J., Wang, X., Liu, L., Yan, H., Lee, S. F., Mony, P., Devanath, A., et al. (2014) · New England Journal of Medicine

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 886

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 848

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

Dagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S. (2006) · The Lancet

Renin-Angiotensin System StudiesBlood Pressure and Hypertension Studies

Cited by 514

Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

Mente, A., O'Donnell, M., Rangarajan, S., Dagenais, G., Lear, S., McQueen, M., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Lanas, F., et al. (2016) · The Lancet

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 483

Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study

Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 476

Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study

St-Pierre, A. C., Cantin, B., Dagenais, G. R., Mauriège, P., Bernard, P.-M., Després, J.-P., & Lamarche, B. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 422

Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study

Mente, A., O'Donnell, M., Rangarajan, S., McQueen, M., Dagenais, G., Wielgosz, A., Lear, S., Ah, S. T. L., Wei, L., Diaz, R., et al. (2018) · The Lancet

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 332

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis

Gerstein, H. C., Pogue, J., Mann, J. F. E., Lonn, E., Dagenais, G. R., McQueen, M., Yusuf, S., & HOPE investigators (2005) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 262

Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study

Smyth, A., Teo, K. K., Rangarajan, S., O'Donnell, M., Zhang, X., Rana, P., Leong, D. P., Dagenais, G., Seron, P., Rosengren, A., et al. (2015) · The Lancet

Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

Cited by 230

Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk

Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2003) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 224

Early cerebral small vessel disease and brain volume, cognition, and gait

Smith, E. E., O'Donnell, M., Dagenais, G., Lear, S. A., Wielgosz, A., Sharma, M., Poirier, P., Stotts, G., Black, S. E., Strother, S., et al. (2015) · Annals of Neurology

Cerebrovascular and genetic disordersDementia and Cognitive Impairment Research

Cited by 207

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 158

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis

Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., Avezum, A., Zhu, J., Liu, L., Sliwa, K., et al. (2021) · The Lancet

Blood Pressure and Hypertension StudiesLipoproteins and Cardiovascular Health

Cited by 151

A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction

Brophy, J. M., Dagenais, G. R., McSherry, F., Williford, W., & Yusuf, S. (2004) · The American Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 136

SYNTAX Score and Long-Term Outcomes

Ikeno, F., Brooks, M. M., Nakagawa, K., Kim, M.-K., Kaneda, H., Mitsutake, Y., Vlachos, H. A., Schwartz, L., Frye, R. L., Kelsey, S. F., et al. (2017) · Journal of the American College of Cardiology

Coronary Interventions and DiagnosticsCardiac Imaging and Diagnostics

Cited by 85

Inflammatory markers and long-term risk of ischemic heart disease in men

St-Pierre, A. C., Cantin, B., Bergeron, J., Pirro, M., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2005) · Atherosclerosis

Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Cited by 67